Study of the effect of goshajinkigan on pelvic floor muscle

Study of the effect of goshajinkigan on pelvic floor muscle - Pelvic floor muscle to 107 study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034512

Enrollment

Registered

2018-10-15

Start date

2018-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder

Interventions

Only existing OAB therapeutic medicine Mirabegron will be administered within 3 months In addition to Mirabegron Medical extract formula Gosha-jinki-gan, 2.5 g once, 3 times a day, 3 months

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Pelvic floor muscle dysfunction patients

Exclusion criteria

Exclusion criteria: Residual urine volume after urination is 100 ml or more Have severe heart disease, liver disease nor kidney disease

Design outcomes

Primary

Measure	Time frame
Changes in questionnaire 3 months after administration	—

Countries

Japan

Contacts

Public ContactNoriko Ninomiya

Women's Clinic LUNA Shinsaibashi Urology

ninomiya5829@yahoo.co.jp06-6251-7505

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026